MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients
- 1 February 2016
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 291, 73-77
Abstract
No abstract availableKeywords
Funding Information
- Convenio de Investigación. Dep. de Salut. Generalitat de Catalunya (352/05)
This publication has 26 references indexed in Scilit:
- Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivityNeurology, 2009
- IFNβ bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assaysJournal of Neuroimmunology, 2007
- Multiple sclerosis: Relating MxA transcription to anti-interferon-β-neutralizing antibodiesNeurology, 2007
- Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patientsMultiple Sclerosis Journal, 2006
- Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosisJournal of Neuroimmunology, 2005
- Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patientsNeurology, 2003
- Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratoryJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-β1aJournal of Interferon & Cytokine Research, 1998
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- EDMUS, a European database for multiple sclerosis.Journal of Neurology, Neurosurgery & Psychiatry, 1992